EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet  ¹     Edward V. Loftus Jr.  ²     Silvio Danese  ³     Severine Vermeire  ⁴     William Sandborn  ⁵     Ronald Fogel  ⁶     Sandeep Nijhawan  ⁷     Radoslaw Kempinski  ⁸     Rafal Filip  ⁹     Ihor Hospodarskyy  ¹⁰     John McNally  ¹¹     Chohee Yun  ¹¹     Sally Zhao  ¹¹     Xiaopeng Liu  ¹¹     Chantal Tasset  ¹²     Robin Besuyen  ¹³     Mamoru Watanabe  ¹⁴     Stefan Schreiber  ¹⁵     Gerhard Rogler  ¹⁶     Toshifumi Hibi  ¹⁷     Brian G. Feagan  ^18    
1 Lorraine University, Vandoeuvre les Nancy, France
² Mayo Clinic College of Medicine, Rochester, United States
³ Humanitas University, Milan, Italy
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ University of California San Diego, La Jolla, United States
⁶ Clinical Research Institute of Michigan, Detroit, United States
⁷ SMS Medical College & Hospital, Jaipur, India
⁸ CM Oporów, Rzeszów, Poland
⁹ Clinical Hospital No. 2, Rzeszów, Poland
¹⁰ Ternopil National Medical University, Voli, Ukraine
¹¹ Gilead Sciences, Inc., Foster City, United States
¹² Galapagos NV, Mechelen, Belgium
¹³ Galapagos BV, Leiden, Netherlands
¹⁴ Tokyo Medical and Dental University, Tokyo, Japan
¹⁵ University Hospital Schleswig-Holstein, Kiel, Germany
¹⁶ University Hospital of Zurich, Zurich, Switzerland
¹⁷ Kitasato University Kitasato Institute Hospital, Tokyo, Japan
¹⁸ Western University, London, Canada

Topic
IBD

Session
Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)